WO2007141203A1 - Pulvérisateur - Google Patents

Pulvérisateur Download PDF

Info

Publication number
WO2007141203A1
WO2007141203A1 PCT/EP2007/055383 EP2007055383W WO2007141203A1 WO 2007141203 A1 WO2007141203 A1 WO 2007141203A1 EP 2007055383 W EP2007055383 W EP 2007055383W WO 2007141203 A1 WO2007141203 A1 WO 2007141203A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
phenyl
chloro
fluoro
methoxy
Prior art date
Application number
PCT/EP2007/055383
Other languages
German (de)
English (en)
Inventor
Dieter Hochrainer
Bernd Zierenberg
Original Assignee
Boehringer Ingelheim International Gmbh
Boehringer Inghelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Boehringer Inghelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim International Gmbh
Priority to EP07729784A priority Critical patent/EP2029205A1/fr
Priority to JP2009512611A priority patent/JP2009538656A/ja
Priority to CA002653422A priority patent/CA2653422A1/fr
Publication of WO2007141203A1 publication Critical patent/WO2007141203A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0066—Inhalators with dosage or measuring devices with means for varying the dose size
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
    • B05B11/109—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle the dispensing stroke being affected by the stored energy of a spring

Definitions

  • the invention relates to a nebulizer for delivering a certain amount of, in particular having a drug, fluid as an aerosol through a nozzle from a pressure accumulator, wherein a mechanical pressure generator applied to the measured fluid in the pressure accumulator, which is to release abruptly for sputtering.
  • EP 0 521 061 B1 discloses a dosing device for dispensing a measured amount of a liquid as a spray with droplets of a size suitable for inhalation into the lungs by dispensing the metered amount of liquid through a nebulizer comprising a chamber for receiving the metered Amount of liquid, an energy storage and means for delivering a predetermined amount of energy to the energy storage comprises.
  • means are provided for releasing the predetermined amount of energy from the energy store to the chamber so as to expose the liquid therein to a predetermined pressure rise from a low pressure to a higher pressure and to initiate a discharge of the liquid from the chamber.
  • a nebulizer is used to nebulize the metered amount of the pressurized fluid.
  • W is a pharmacologically active agent and (for example) selected from the group consisting of betamimetics, anticholinergics, corticosteroids, PDE4 inhibitors, LTD4 antagonists, EGFR inhibitors, dopamine agonists, HI antihistamines, P AF - antagonists and PI3-kinase inhibitors. Furthermore, two- or three-fold combinations of W can be combined and used for application in the device according to the invention.
  • W represents a betamimetics combined with anticholinergics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • W represents an anticholinergic agent combined with a betamimetics, corticosteroids, PDE4 inhibitors, EGFR inhibitors or LTD4 antagonists
  • - W represents a corticosteroid combined with a PDE4 inhibitor, EGFR inhibitor or LTD4 antagonist
  • W represents a PDE4 inhibitor combined with an EGFR inhibitor or LTD4 antagonist
  • W represents an EGFR inhibitor combined with a LTD4 antagonist.
  • Preferred betamimetics for this purpose are compounds selected from the group consisting of albuterol, arformoterol, bambuterol, bitolertrol, broxaterol, carbuterol, clenbuterol, fenoterol, formoterol, hexoprene cream, ibuterol, isoethanol, isoprenalm, levosalbutamol, mabuterol, meluadnone , Metaproterenol, orciprene cream, pirbuterol, procaterol, reproterol, rimiterol, ritodnone, salmefamol, salmetrol, soterenol, sulphoneterol, terbutaline, tiaramide, toluubuterol, zinterol, CHF-1035, HOKU-81, KUL-1248 and
  • the acid addition salts of the betamimetics are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate ,
  • Preferred anticholinergic compounds are compounds which are selected from the group consisting of tiotropium salts, preferably the bromide salt, oxitropium salts, preferably the bromide salt, flutropium salts, preferably the bromide salt, ipratropium salts, preferably the bromide salt, glycopyrronium salts, preferably the bromide salt Trospium salts, preferably the chloride salt, tolterodine.
  • the cations are the pharmacologically active constituents.
  • the abovementioned salts may preferably contain chloride, bromide, iodine, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate,
  • Oxalate, succinate, benzoate or p-toluenesulfonate with chloride, bromide, iodide, sulfate, methanesulfonate or p-toluenesulfonate being preferred as counterions.
  • chlorides, bromides, iodides and methanesulfonates are particularly preferred.
  • X is a single negatively charged anion, preferably an anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate and p-Toluene sulfonate, preferably a singly negatively charged anion, more preferably an anion selected from the group consisting of fluoride, chloride, bromide, methanesulfonate and p-toluenesulfonate, most preferably bromide, optionally in the form of their racemates, enantiomers or hydrates.
  • anion selected from the group consisting of fluoride, chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, cit
  • AC-2 wherein R is either methyl or ethyl and in which X 'may have the abovementioned meanings.
  • the compound of the formula AC-2 may also be present in the form of the free base AC-2-base.
  • Preferred corticosteroids are compounds selected from the group consisting of beclomethasone, betamethasone, budesonide, butixocort, ciclesonide, deflazacort, dexamethasone, etiprednol, flunisolide, fluticasone, loteprednol, mometasone, prednisolone, prednisone, rofleponide, triamcinolone , RPR-106541, NS-126, ST-26 and - 6,9-difluoro-17 - [(2-furanylcarbonyl) oxy] -1-hydroxy-16-methyl-3-oxo-androsta-1, 4- dien-17-carbothionic acid (S) -fluoromethyl ester
  • Examples of possible salts and derivatives of the steroids may be: alkali metal salts, such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
  • alkali metal salts such as, for example, sodium or potassium salts, sulfobenzoates, phosphates, isonicotinates, acetates, dichloroacetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates.
  • Preferred PDE4 inhibitors are compounds selected from the group consisting of enprofylline, theophylline, roflumilast, A- ⁇ flo (cilomilast), tofimilast, pumafent ⁇ n, Li ⁇ milast, Arofyllm, Atizoram, D-4418, Bay 198004, BY343, CP-325,366, D-4396 (Sch-351591), AWD-12-281 (GW-842470), NCS-613, CDP-840, D-4418, PD-168787, T-440, T-2585, V-11294A, Cl-1018, CDC-801, CDC-3052, D-22888, YM-58997, Z-15370 and
  • the acid addition salts of the PDE4 inhibitors are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate , Hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate
  • Preferred LTD4 antagonists here are compounds selected from the group consisting of montelukast, pranlukast, zafirlukast, MCC-847 (ZD-3523), MN-001, MEN-91507 (LM-1507), VUF-5078 , VUF-K-8707, L-733321 and - l - (((R) - (3- (2- (6,7-difluoro-2-quinohnyl) ethenyl) phenyl) -3- (2
  • Alkali salts such as, for example, sodium or potassium salts, alkaline earth salts, sulfobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or even furoates
  • the EGFR inhibitors used are preferably compounds selected from the group consisting of cetuximab, trastuzumab, ABX-EGF, Mab ICR-62 and - 4 - [(3-chloro-4-fluorophenyl) amino] -6- ⁇ [4- (morphony-4-yl) -1-oxo-2-buten-1-yl] amino ⁇ -
  • these acid addition salts are preferred selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate,
  • Hydromethanesulfonate hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotaitrat, hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate
  • Preferred dopamine agonists are compounds which are selected from the group consisting of bromocidin, cabergolm, alpha-dihydroergocryptine, lisium, pergohd, pramipexole, roxindole, ropinirole, tahpexol, tergucone and viozane, optionally in the form of their racemates Enantiomers, diastereomers and optionally in the form of their pharmacologically acceptable acid addition salts, solvates or hydrates According to the invention, these acid addition salts are selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotaitrat , Hydrooxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate
  • Hl -Antihistaminika here preferably compounds are used, which are selected from the group consisting of epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, Emedastm, Dimetinden, Clemastin, Bamipm, Cexchlorpheniramin, pheniram, Doxylamin , Chlorphenoxamm, Dimenhydn- nat, diphenhydramine, promethazine, ebastine, Desloratidm and meclocine, optionally in
  • these acid addition salts are preferably selected from the group consisting of Hydrochloride, hydrobromide, hydroiodide, hydrosulfate, hydrophosphate, hydromethanesulfonate, hydronitrate, hydromaleate, hydroacetate, hydrocitrate, hydrofumarate, hydrotartrate, hydroxalate, hydrosuccinate, hydrobenzoate and hydro-p-toluenesulfonate
  • substance formulations or mixtures of substances all inhalable compounds are used, such as, for example, inhalable macromolecules, as disclosed in EP 1 003 478.
  • substances, substance formulations or substance mixtures are used for the treatment of respiratory diseases, which are used in the inhalation area.
  • the object is achieved in that the nozzle is associated with a nose piece
  • the nose piece can be used in at least one of the nostrils and by means of the atomizer the fluid is evenly and reproducibly nebulized for absorption through the mucous membranes.
  • the finely distributed fluid passes in fine particles on the nasal mucous membranes, from where the active ingredient Diffusion either directly reaches its site of action or enters the bloodstream and thus reaches its effective range. Due to the distribution over a large area of the nasal mucosa, a high bioavailability is given.
  • the nose piece is advantageously removably attached.
  • the nozzle is arranged in a mouthpiece of the atomizer, which carries the nose piece sealed.
  • the nebulizer with the mouthpiece in a known manner as an inhaler for administering a particular respirable fluid for respiratory treatment and with the nosepiece attached to the mouthpiece, which can also be referred to as nose tube, for the nasal application of solutions, suspensions and so-called Solutions, namely a mixture of solution and suspension to use.
  • a known atomizer is offered under the trade name "Respimat" by Boehringer Ingelheim KG in the form of an inhaler and is shown in WO 91/14468 A1 as well as WO 97/12687 A1.
  • the nosepiece in the attachment area assigned to the mouthpiece preferably has a geometry which is congruent to the mouthpiece. Due to this measure, it is not necessary to provide a seal between the Aufsteck Scheme the nose piece and the mouthpiece. Rather, a contour-dependent positive sealing is given after placement of the nose piece.
  • the attachment area of the nosepiece is expediently elliptical in cross-section.
  • the nose insertion area of the nosepiece is preferably elliptically shaped.
  • the opening in the Naseneincertify College is smaller than the opening dimensioned in Aufsteck Bachelor.
  • the cross section of the nose piece narrows continuously from the attachment area to the nasal insertion area.
  • the pressure generator comprising a piston comprises a holder for the reservoir, an associated drive spring with a release button and a conveyor tube, wherein axial tensioning of the drive spring displaces the support with the reservoir and the delivery tube in a direction opposite the nosepiece and sucks fluid from a reservoir into the pressure chamber.
  • the specific amount is adjustable.
  • an actuation of the release button causes a relaxation of the tensioned drive spring, which moves the delivery tube in the direction of the nosepiece and thereby pressurizes the fluid for discharge through the nozzle.
  • a non-return valve is associated with the delivery pipe.
  • a reservoir for the fluid is interchangeably disposed within a housing.
  • the nozzle comprises a nozzle channels for generating two spray jets meeting one another for producing a spray system associated with a spray cloud.
  • the nozzle channels are designed such that two approximately at a right angle to each other impinging spray jets are formed.
  • the filter system associated with the nozzle channels causes retention of solid particles and prevents clogging of the nozzle channels.
  • the nozzle comprises a filter system and at least two nozzle channels for generating at least two spray jets meeting one another to produce a spray cloud.
  • Fig. 1 is a sectional view of an atomizer according to the invention.
  • FIG. 2 shows a schematic plan view of a nose piece of the atomizer according to FIG. 1.
  • the nebulizer 1 is used for nebulizing a fluid 2, in particular a highly effective drug, and is designed as a portable inhaler, which operates without propellant gas.
  • a fluid 2 in particular a highly effective drug
  • a portable inhaler which operates without propellant gas.
  • an aerosol is formed, which can be inhaled by a user, not shown.
  • the atomizer 1 has an exchangeable storage container 3 with the fluid 2, which has a substantially cylindrical structure and can be inserted from below into the opened atomizer 1.
  • the atomizer 1 comprises a pressure generator 5 comprising a piston 24 with a holder 6 for the container 3, a drive spring 7 with a release button 8 which can be manually actuated for relaxation, a delivery tube 9 with an inserted non-return valve 10, a pressure chamber 11 and a nozzle 12 to which a mouthpiece 13 is assigned.
  • the support 6 is moved downwards with the storage container 3 and the delivery pipe 9 and fluid from the container 3 sucked via the check valve 10 in the piston 24 of the pressure generator 5 associated pressure chamber 11.
  • the fluid 2 is pressurized in the pressure chamber 11 of the conveyor tube 9 upwardly displacing the drive spring 7 and discharged through the nozzle 12, wherein a sputtering takes place.
  • the atomization takes place, for example, in particles in the ⁇ m range, preferably in particles with a size of about 20 ⁇ m, which form a cloud or a jet of an aerosol.
  • a user can inhale the aerosol, wherein supply air can be sucked into the mouthpiece 13 via supply air openings 15.
  • a nose piece 19 is detachably attached to the mouthpiece 13.
  • the nosepiece 19 has a geometry which is congruent to the mouthpiece 13 and is substantially elliptical in cross-section both in the attachment region 20 and in the nose insertion region 21.
  • the opening 22 in the nasal introduction area 21 of the nose piece 19 is smaller than the opening 23 in the attachment area 20 and widens continuously up to the attachment area 20 which is sealed against the mouthpiece 13.
  • the dimensions of the nosepiece 19 are, of course, the dimensions of a human nostril adapted, wherein the dimensions of the largest and the smallest outer diameter, for example, 16 mm and 10 mm

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un pulvérisateur (1), destiné à délivrer une quantité définie d'un fluide (2), en particulier contenant un médicament, sous la forme d'un aérosol à travers une buse (12) à partir d'un réservoir sous pression (11) au moyen d'un générateur de pression mécanique (5) qui applique au fluide (2) dosé dans le réservoir une pression qui doit être libérée brusquement pour la pulvérisation. Selon l'invention, la buse (12) est associée à un embout nasal (19).
PCT/EP2007/055383 2006-06-02 2007-06-01 Pulvérisateur WO2007141203A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07729784A EP2029205A1 (fr) 2006-06-02 2007-06-01 Pulvérisateur
JP2009512611A JP2009538656A (ja) 2006-06-02 2007-06-01 アトマイザ
CA002653422A CA2653422A1 (fr) 2006-06-02 2007-06-01 Pulverisateur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006025871A DE102006025871A1 (de) 2006-06-02 2006-06-02 Zerstäuber
DE102006025871.1 2006-06-02

Publications (1)

Publication Number Publication Date
WO2007141203A1 true WO2007141203A1 (fr) 2007-12-13

Family

ID=38472898

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/055383 WO2007141203A1 (fr) 2006-06-02 2007-06-01 Pulvérisateur

Country Status (5)

Country Link
EP (1) EP2029205A1 (fr)
JP (1) JP2009538656A (fr)
CA (1) CA2653422A1 (fr)
DE (1) DE102006025871A1 (fr)
WO (1) WO2007141203A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009153049A1 (fr) * 2008-06-20 2009-12-23 Boehringer Ingelheim International Gmbh Inhalateur
US7837235B2 (en) 2004-01-08 2010-11-23 Boehringer Ingelheim International Gmbh Device for clamping a fluidic component
US7963955B2 (en) 1998-02-27 2011-06-21 Boehringer Ingelheim International Gmbh Container for a medicinal liquid
JP2012530567A (ja) * 2009-06-25 2012-12-06 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
DE102013013397A1 (de) * 2013-08-13 2015-03-12 Epinamics Gmbh Aerosolspender für transdermal wirkende pharmazeutische Zusammensetzungen
US9545487B2 (en) 2012-04-13 2017-01-17 Boehringer Ingelheim International Gmbh Dispenser with encoding means
CN106456915A (zh) * 2014-05-14 2017-02-22 技术合伙公司 用于液体药物递送背景的雾化引擎
US9682202B2 (en) 2009-05-18 2017-06-20 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US9724482B2 (en) 2009-11-25 2017-08-08 Boehringer Ingelheim International Gmbh Nebulizer
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
US9757750B2 (en) 2011-04-01 2017-09-12 Boehringer Ingelheim International Gmbh Medicinal device with container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
US10004857B2 (en) 2013-08-09 2018-06-26 Boehringer Ingelheim International Gmbh Nebulizer
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US10099022B2 (en) 2014-05-07 2018-10-16 Boehringer Ingelheim International Gmbh Nebulizer
US10124129B2 (en) 2008-01-02 2018-11-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
US10124125B2 (en) 2009-11-25 2018-11-13 Boehringer Ingelheim International Gmbh Nebulizer
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
FR3121047A1 (fr) * 2021-03-29 2022-09-30 Aptar France Sas Dispositif de distribution nasale de poudre

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014310916B2 (en) 2013-08-20 2018-10-18 Boehringer Ingelheim Vetmedica Gmbh Inhaler
CA2913828C (fr) 2013-08-20 2022-04-12 Boehringer Ingelheim Vetmedica Gmbh Inhalateur
DK3035886T3 (da) 2013-08-20 2021-01-04 Boehringer Ingelheim Vetmedica Gmbh Inhalator
CN113679910A (zh) * 2020-05-19 2021-11-23 顾瑜 雾化装置

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3820698A (en) * 1971-08-31 1974-06-28 Boehringer Sohn Ingelheim Device for spraying liquid pharmaceuticals
WO1991014468A1 (fr) * 1990-03-21 1991-10-03 Dmw (Technology) Limited Dispositifs et procedes de pulverisation
GB2291135A (en) * 1994-07-06 1996-01-17 Boehringer Ingelheim Kg Device for dispensing fluid
WO1998039043A1 (fr) * 1997-03-03 1998-09-11 Alfred Von Schuckmann Appareil permettant la distribution dosee de substances
WO2003002045A1 (fr) * 2001-06-29 2003-01-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nebuliseurs servant a appliquer des liquides sur la cornee
US20030226907A1 (en) * 2002-05-16 2003-12-11 Boehringer Ingelheim International Gmbh System comprising a nozzle and a fixing means therefor
WO2005079997A1 (fr) * 2004-02-24 2005-09-01 Boehringer Ingelheim International Gmbh Pulverisateur
US20050268915A1 (en) * 2004-06-07 2005-12-08 Willem Wassenaar Nasal adaptation of an oral inhaler device

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3820698A (en) * 1971-08-31 1974-06-28 Boehringer Sohn Ingelheim Device for spraying liquid pharmaceuticals
WO1991014468A1 (fr) * 1990-03-21 1991-10-03 Dmw (Technology) Limited Dispositifs et procedes de pulverisation
GB2291135A (en) * 1994-07-06 1996-01-17 Boehringer Ingelheim Kg Device for dispensing fluid
WO1998039043A1 (fr) * 1997-03-03 1998-09-11 Alfred Von Schuckmann Appareil permettant la distribution dosee de substances
WO2003002045A1 (fr) * 2001-06-29 2003-01-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nebuliseurs servant a appliquer des liquides sur la cornee
US20030226907A1 (en) * 2002-05-16 2003-12-11 Boehringer Ingelheim International Gmbh System comprising a nozzle and a fixing means therefor
WO2005079997A1 (fr) * 2004-02-24 2005-09-01 Boehringer Ingelheim International Gmbh Pulverisateur
US20050268915A1 (en) * 2004-06-07 2005-12-08 Willem Wassenaar Nasal adaptation of an oral inhaler device

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7963955B2 (en) 1998-02-27 2011-06-21 Boehringer Ingelheim International Gmbh Container for a medicinal liquid
US7837235B2 (en) 2004-01-08 2010-11-23 Boehringer Ingelheim International Gmbh Device for clamping a fluidic component
US9027967B2 (en) 2004-01-08 2015-05-12 Boehringer Ingelheim International Gmbh Device for clamping a fluidic component
US10124129B2 (en) 2008-01-02 2018-11-13 Boehringer Ingelheim International Gmbh Dispensing device, storage device and method for dispensing a formulation
EP2135632A1 (fr) * 2008-06-20 2009-12-23 Boehringer Ingelheim International Gmbh Inhalateur
JP2011524228A (ja) * 2008-06-20 2011-09-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
WO2009153049A1 (fr) * 2008-06-20 2009-12-23 Boehringer Ingelheim International Gmbh Inhalateur
US10011906B2 (en) 2009-03-31 2018-07-03 Beohringer Ingelheim International Gmbh Method for coating a surface of a component
US9682202B2 (en) 2009-05-18 2017-06-20 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
JP2012530567A (ja) * 2009-06-25 2012-12-06 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング 吸入器
US10124125B2 (en) 2009-11-25 2018-11-13 Boehringer Ingelheim International Gmbh Nebulizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
US9724482B2 (en) 2009-11-25 2017-08-08 Boehringer Ingelheim International Gmbh Nebulizer
US9943654B2 (en) 2010-06-24 2018-04-17 Boehringer Ingelheim International Gmbh Nebulizer
US9757750B2 (en) 2011-04-01 2017-09-12 Boehringer Ingelheim International Gmbh Medicinal device with container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
US10220163B2 (en) 2012-04-13 2019-03-05 Boehringer Ingelheim International Gmbh Nebuliser with coding means
US9545487B2 (en) 2012-04-13 2017-01-17 Boehringer Ingelheim International Gmbh Dispenser with encoding means
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
US10004857B2 (en) 2013-08-09 2018-06-26 Boehringer Ingelheim International Gmbh Nebulizer
US10894134B2 (en) 2013-08-09 2021-01-19 Boehringer Ingelheim International Gmbh Nebulizer
US11642476B2 (en) 2013-08-09 2023-05-09 Boehringer Ingelheim International Gmbh Nebulizer
DE102013013397A1 (de) * 2013-08-13 2015-03-12 Epinamics Gmbh Aerosolspender für transdermal wirkende pharmazeutische Zusammensetzungen
US10716905B2 (en) 2014-02-23 2020-07-21 Boehringer Lngelheim International Gmbh Container, nebulizer and use
US10099022B2 (en) 2014-05-07 2018-10-16 Boehringer Ingelheim International Gmbh Nebulizer
US10195374B2 (en) 2014-05-07 2019-02-05 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
CN106456915A (zh) * 2014-05-14 2017-02-22 技术合伙公司 用于液体药物递送背景的雾化引擎
FR3121047A1 (fr) * 2021-03-29 2022-09-30 Aptar France Sas Dispositif de distribution nasale de poudre
WO2022208014A1 (fr) 2021-03-29 2022-10-06 Aptar France Sas Dispositif de distribution nasale de poudre

Also Published As

Publication number Publication date
CA2653422A1 (fr) 2007-12-13
JP2009538656A (ja) 2009-11-12
DE102006025871A1 (de) 2007-12-06
EP2029205A1 (fr) 2009-03-04

Similar Documents

Publication Publication Date Title
WO2007141203A1 (fr) Pulvérisateur
EP3508239B1 (fr) Adaptateur, dispositif d'inhalation et pulvérisateur
JP5681492B2 (ja) ノズル、吸入器及びノズルの製造方法
EP2015811B1 (fr) Pulvérisateur et procédé de pulverisation d'un fluide
JP5719291B2 (ja) 吸入器
EP2023990A1 (fr) Adaptateur avec raccord pour pulvérisateur
EP2066380B1 (fr) Inhalateur
MX2011013077A (es) Inhalador.
EP2066382B1 (fr) Doseur à piston
ES2734501T3 (es) Boquilla para un inhalador
EP2007459A1 (fr) Inhalateur
JP5504156B2 (ja) 吸入器
EP2424603B1 (fr) Dispositif d'inhalation
WO2008034505A1 (fr) Inhalateur
EP2001601A1 (fr) Aérosols de dosage pour l'administration de préparations pharmaceutiques
EP2198972A1 (fr) Réservoir et gicleur

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07729784

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2653422

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007729784

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009512611

Country of ref document: JP